Any current/future capex/capital investment/strategic investment?

Morepen Laboratories is completing the expansion of API manufacturing capacity from 314 KL to 600 KL, nearly doubling capacity, expected to be completed within FY '26. After the 600 KL capacity expansion, there are no immediate plans for further capacity increases. The company is exploring partnerships with outsourcing vendors who have surplus capacity or complementary product mixes. Investment is ongoing in backward integration, especially in the medical devices segment, aiming to increase EBITDA margins. There is focus on expanding formulations and OTC products, including hiring new teams an

Future growth expectations in sales/revenue/volumes?

The company expects overall growth of 10% to 15% at the company level for FY '26 and FY '27. Finished dosage business has shown a 21% growth in 2 years, with expectations of higher growth than API segment. API business growth has been muted (~3-4%), but capacity expansion from 314 KL to 600 KL by FY '26 is expected to boost revenues. Export focus is increasing, with export revenues growing 26% over 3 years; export now constitutes 72% of business. Medical devices segment is expanding capacity significantly (e.g., BP monitors capacity doubling from 9 to 18 lakh units) and expected to del

Future growth expectations in earnings/operating earnings/profits/EPS?

The company generally does not give formal guidance but indicates expected growth of 10% to 15% at the company level for FY '26 and FY '27. EBITDA is expected to increase, particularly due to product mix improvements: - API business EBITDA to grow with capacity expansion and increased exports. - Finished dosage (formulations) business has higher margins (around 70%) compared to API (30-40%) and is expected to improve EBITDA, with some investment phase in initial years. - Medical devices segment continues consistent volume growth, boosting EBITDA. Operating expenses are being ti

Current/ Expected Orderbook/ Pending Orders?

The company has 600 KL capacity planned for FY '26, expected to be completed within the year. Current installed capacity is 514 KL as part of capacity expansion (91% increase targeted). They are working on building a good outsourcing partner network to manage excess demand or capacity shortage. Despite a recent price drop of 24%, quantity sold has increased by 57% in APIs, indicating robust order intake. Some export orders (US and Europe) were deferred last quarter, impacting short-term revenues. Management is in a "wait and watch" mode regarding price acceptance by Indian customers due to rec

Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the transcript. The company is focused on organic growth through capacity expansion (e.g., completing 600 KL API capacity by FY '26). Discussions emphasize revenue growth, margin improvement, and operational efficiencies rather than funding needs. No comments were made about raising capital to fund these expansions or for any other purposes. The management's strategy indicates reliance on internal resources, customer partnerships, and outsourcing rather than external fundraising. No specific plans or i

IN US

Sale is live|00:00:00left today

Morepen Laboratories LtdQ1 FY25Pharmaceuticals & Biotechnology

Morepen Laboratories Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹53.2P/E: 30.1Market Cap: ₹2.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company expects overall growth of 10% to 15% at the company level for FY '26 and FY '27.
→Finished dosage business has shown a 21% growth in 2 years, with expectations of higher growth than API segment.
→API business growth has been muted (~3-4%), but capacity expansion from 314 KL to 600 KL by FY '26 is expected to boost revenues.
→Export focus is increasing, with export revenues growing 26% over 3 years; export now constitutes 72% of business.
→Medical devices segment is expanding capacity significantly (e.g., BP monitors capacity doubling from 9 to 18 lakh units) and expected to deliver strong growth given health awareness trends.
→The new molecule contribution in API is rising, forecasting faster growth in this segment.
→Expansion in manpower, particularly medical representatives (from 200 to 1,200 over 3 years), is expected to drive formulation sales growth.
→Long-term EBITDA growth is expected, linked to product mix improvements, exports, and capacity increases.

Margin guidance

Category 3

→The company generally does not give formal guidance but indicates expected growth of 10% to 15% at the company level for FY '26 and FY '27.
→EBITDA is expected to increase, particularly due to product mix improvements:
→ - API business EBITDA to grow with capacity expansion and increased exports.
→ - Finished dosage (formulations) business has higher margins (around 70%) compared to API (30-40%) and is expected to improve EBITDA, with some investment phase in initial years.
→ - Medical devices segment continues consistent volume growth, boosting EBITDA.
→Operating expenses are being tightly controlled amid lower sales realizations.
→With capacity expansion (e.g., API capacity doubled to 600 KL expected by FY '26 end) and increased outsourcing partnerships, revenues and margins are projected to improve.
→Overall, improvements in revenue, EBITDA, and PAT margins are anticipated through strategic product and market focus.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned fundraising through debt or equity in the transcript.
→The company is focused on organic growth through capacity expansion (e.g., completing 600 KL API capacity by FY '26).
→Discussions emphasize revenue growth, margin improvement, and operational efficiencies rather than funding needs.
→No comments were made about raising capital to fund these expansions or for any other purposes.
→The management's strategy indicates reliance on internal resources, customer partnerships, and outsourcing rather than external fundraising.
→No specific plans or intentions to issue new equity or take on additional debt were disclosed during the call.

Order book

→The company has 600 KL capacity planned for FY '26, expected to be completed within the year.
→Current installed capacity is 514 KL as part of capacity expansion (91% increase targeted).
→They are working on building a good outsourcing partner network to manage excess demand or capacity shortage.
→Despite a recent price drop of 24%, quantity sold has increased by 57% in APIs, indicating robust order intake.
→Some export orders (US and Europe) were deferred last quarter, impacting short-term revenues.
→Management is in a "wait and watch" mode regarding price acceptance by Indian customers due to recent raw material price increases and global market conditions.
→They are ready to compromise on revenue short term (1-2 months or quarters) but will not go below certain price levels.
→Confident that API prices have almost bottomed out, implying a more stable orderbook and pricing environment ahead.

Capex plans

Yes

→Morepen Laboratories is completing the expansion of API manufacturing capacity from 314 KL to 600 KL, nearly doubling capacity, expected to be completed within FY '26.
→After the 600 KL capacity expansion, there are no immediate plans for further capacity increases.
→The company is exploring partnerships with outsourcing vendors who have surplus capacity or complementary product mixes.
→Investment is ongoing in backward integration, especially in the medical devices segment, aiming to increase EBITDA margins.
→There is focus on expanding formulations and OTC products, including hiring new teams and launching products in new markets like the U.S. via Amazon.
→R&D investments continue with 55 scientists, 168 patents filed, and development of new molecules to drive future growth.

How does Morepen Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Morepen Laboratories Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Morepen Laboratories Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio